Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Here is how Bausch Health (BHC) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Bausch Health (BHC) This Year?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term

BHC's third-quarter adjusted earnings and revenues beat estimates. The increase in revenue guidance is positive.

Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales

While the top- and bottom-line numbers for Bausch (BHC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Bausch (BHC) Q3 Earnings: A Look at Key Metrics

Bausch Health (BHC) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.03 per share a year ago.

Bausch Health (BHC) Beats Q3 Earnings and Revenue Estimates

Bausch Health Companies, Inc. (NYSE:BHC ) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Conference Call Participants Mike Kovich - Cowen Les Sulewski - Truist Securities Umer Raffat - Evercore ISI David Amsellem - Piper Sandler Glen Santangelo - Jefferies Michael Freeman - Raymond James Operator Greetings. Welcome to the Bausch Health Third Quarter 2024 Earnings Call.

Bausch Health Companies, Inc. (BHC) Q3 2024 Earnings Call Transcript

National HealthCare

Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1 Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic (non-GAAP)1 basis, with growth in all segments Consolidated GAAP Net Loss Attributable to Bausch Health Companies Inc. of $85 million Consolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $909 million, up 10% Raising full-year 2024 guidance LAVAL, QC / ACCESSWIRE / October 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2024 financial results and other key updates from the quarter. "Our team at Bausch Health continued to execute against our commitments in the third quarter, delivering a sixth consecutive quarter of year-over-year growth in both revenue and Adjusted EBITDA.

Bausch Health Announces Third Quarter 2024 Results

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2024 financial results. “Our focus on execution continues to drive growth, with significant opportunity ahead,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “We're in the middle of multi-dimensional launch cycles around the world, covering all our businesses and targeting all our audie.

Bausch + Lomb Announces Third-Quarter 2024 Results

Additional ACG presentation to focus on impact of Xifaxan on OHE rehospitalizations LAVAL, QC / ACCESSWIRE / October 27, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced that results of an analysis of Xifaxan® (rifaximin) monotherapy will be presented during a Presidential Plenary Session of The American College of Gastroenterology® 2024 Annual Scientific Meeting taking place October 25-30 in Philadelphia, PA. This post hoc analysis of data from two randomized trials evaluated the efficacy of Xifaxan monotherapy compared to lactulose monotherapy for risk reduction of overt hepatic encephalopathy (OHE) recurrence and all-cause mortality.

ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bausch Health (BHC) Reports Next Week: What to Expect

Blackstone Group

Private equity firms TPG and Blackstone are joining forces in a bid to acquire eye care company Bausch + Lomb BLCO, the Financial Times reported.

Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has approved the enVista® Envy™ full range of vision intraocular lens (IOL), which offers a continuous range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform. “We're confident that U.S. surgeons will agree with what their Canadian.

Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens

LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live webcast at 5:00 p.m.

Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2024 financial results on Wednesday, October 30, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the star.

Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30

Findings show care for chronic liver disease patients is falling on non-specialists who need stronger education and support to ensure patients receive timely, optimal care1 LAVAL, QC / ACCESSWIRE / October 8, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today released Liver Health Trends Report in Action, the latest Liver Health Annual Trends Report dedicated to sparking actionable change to improve liver disease management and outcomes for patients. Healthcare provider (HCP) survey participants called for holistic, multi-disciplinary treatment approaches, consistent use of non-invasive screening tools (e.g.

Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Opal, a digital e-commerce marketplace. Designed to help maximize efficiencies for eye care practices while enhancing the patient experience, Opal provides a streamlined ordering process for Bausch + Lomb contact lenses, with select Bausch + Lomb over-the-counter products to be added in the co.

Bausch + Lomb Launches Opal™ Digital Marketplace in the United States

Bausch Health NYSE: BHC stock has been on a wild ride recently, with a dramatic surge in value over the last month. The catalyst for this surge is a wave of rumors suggesting that Bausch + Lomb NYSE: BLCO, Bausch Health's spinoff eye care business, is considering a buyout.

Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value

BHC stock rises 14.7% in a week after a report surfaced that the company is in talks with Jefferies Financial Group to push out maturities on some of its debt.

Here's Why Bausch Health Stock Gained 14.7% in a Week

Rubrik Inc

VeriSign

Tom Yeung here with your Sunday Digest.  During the early 1990s real estate crisis, the Marriott Corp. hotel chain found itself in trouble.

3 Stocks Billionaires Are Buying Now

Bausch Health's debt burden and potential bankruptcy risks are mitigated by the likely sale of Bausch + Lomb, which could fetch a premium price. Bausch + Lomb's stable business and the recent acquisition of XIIDRA position it well for a sale, potentially valuing it at $10bn-$18bn. Hedge fund managers Carl Icahn and Paulson & Co. are major stakeholders at Bausch Health, reducing bankruptcy risk and supporting a strategic sale of Bausch + Lomb.

Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely

Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Bausch (BHC) Surges 11.7%: Is This an Indication of Further Gains?

Bausch + Lomb stock has rebounded since January, but still offers value, especially with potential takeover interest and a solid balance sheet. BLCO shares trade at a reasonable premium to forward earnings, with a current ratio of 1.66, providing flexibility despite recent unprofitability. Risks include potential failure of takeover, economic downturns, inflation, and majority ownership by BHC, which could affect independent operations.

With Buyout Interest, Bausch + Lomb May Still Be Worth Interest At Current Levels

Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don't think like your typical corporate board, writes Ken Squire of 13D Monitor.

Op-ed: Here's why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors

Eye-care company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported.

Bausch + Lomb's stock soars 18% on report company is considering selling itself

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

News for Bausch Health Companies Inc Stock (BHC)